RT Journal Article
SR Electronic
T1 Optimizing vaccine allocation for COVID-19 vaccines: potential role of single-dose vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.31.20249099
DO 10.1101/2020.12.31.20249099
A1 Matrajt, Laura
A1 Eaton, Julia
A1 Leung, Tiffany
A1 Dimitrov, Dobromir
A1 Schiffer, Joshua T.
A1 Swan, David A.
A1 Janes, Holly
YR 2021
UL http://medrxiv.org/content/early/2021/04/15/2020.12.31.20249099.abstract
AB Most COVID-19 vaccines require two doses, however with limited vaccine supply, policymakers are considering single-dose vaccination as an alternative strategy. Using a mathematical model combined with optimization algorithms, we determined optimal allocation strategies with one and two doses of vaccine under various degrees of viral transmission. Under low transmission, we show that the optimal allocation of vaccine vitally depends on the single-dose efficacy (SDE). With high SDE, single-dose vaccination is optimal, preventing up to 22% more deaths than a strategy prioritizing two-dose vaccination for older adults. With low or moderate SDE, mixed vaccination campaigns with complete coverage of older adults are optimal. However, with modest or high transmission, vaccinating older adults first with two doses is best, preventing up to 41% more deaths than a singledose vaccination given across all adult populations. Our work suggests that it is imperative to determine the efficacy and durability of single-dose vaccines, as mixed or single-dose vaccination campaigns may have the potential to contain the pandemic much more quickly.Competing Interest StatementThe authors have declared no competing interest.Funding StatementLM was supported by Fred Hutchinson Cancer Research Center discretionary funds awarded to Peter Gilbert and to the Scientific Computing Infrastructure at Fred Hutch funded by ORIP grant S10OD028685. HJ was supported by R56AI143418 and R01CA152089 from the National Institutes of Health. DD, JTS and DAS were supported by NU38OT000297-02 from Centers for Disease Control and Prevention.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data/code available upon request.